Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity
Open Access
- 14 November 2008
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 124 (2), 483-489
- https://doi.org/10.1002/ijc.23964
Abstract
Cyclin D1 is a well‐known cell cycle regulator. Recently, its pro‐survival function has been revealed in several tumors. Because increasing expression of cyclin D1 is a common event in oral squamous cell carcinoma (OSCC) and has been correlated with cisplatin resistance, we investigated if cyclin D1 inhibition could increase cisplatin chemosensitivity of OSCC. Five cyclin D1 shRNAs were prepared and 3 were selected for subsequent experiments. IC50 values for cisplatin were determined by an MTT assay. Cisplatin‐induced apoptosis and cell cycle block were investigated. A tumor transplantation model was generated to examine the cisplatin sensitivity of Tca/cisplatin after in vivo cyclin D1 silencing. The role of nuclear factor‐κB (NF‐κB) and cyclin‐dependent kinase 4 (CDK4) in cyclin D1‐mediated cisplatin resistance was also examined. The most effective shRNA resulted in 84.51% knockdown of the cyclin D1 protein level. After the transfection with the 2 most effective shRNAs, the cisplatin IC50 decreased from 5.88 μg/ml to 1.36 μg/ml and 2.47 μg/ml, although overexpression of cyclin D1 rendered OSCC cells more resistant to cisplatin treatment (IC50 increased from 6.43 μg/ml to 12.24 μg/ml). This decreasing IC50 was correlated with the down‐regulation of cisplatin‐induced NF‐κB activity in cyclin D1 knockdown cells, and was independent of CDK4 function. In vivo tumor transplantation models also confirmed a cisplatin‐sensitizing effect of cyclin D1 shRNA in OSCC. A TUNEL assay validated the increase in apoptosis as induced by cisplatin in cyclin D1 knockdown cells. Cyclin D1 may be an important target for future therapy in patients with OSCC.Keywords
This publication has 19 references indexed in Scilit:
- c-Myc–Induced Chemosensitization Is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-κB Activity in Pancreatic Cancer CellsClinical Cancer Research, 2007
- Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in ratsAmerican Journal of Physiology-Renal Physiology, 2006
- Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-κB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHaJournal of Endocrinology, 2006
- p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neckActa Oncologica, 2006
- Overexpression of Cyclin D1 Promotes Tumor Cell Growth and Confers Resistance to Cisplatin-Mediated Apoptosis in an Elastase-myc Transgene–Expressing Pancreatic Tumor Cell LineClinical Cancer Research, 2005
- Cyclin D1 and Pancreatic Carcinoma: A Proliferative Agonist and Chemotherapeutic AntagonistClinical Cancer Research, 2005
- Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 SubunitClinical Cancer Research, 2004
- Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.JCI Insight, 1998
- G1 phase progression: Cycling on cueCell, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993